Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation

详细信息    查看全文

• 作者：Giovanna Lucchini¹ ; ^{Giovanna.Lucchini@gosh.nhs.uk} ; Myriam Labopin² ; Eric Beohou² ; Arnauld Dalissier² ; Jean Hughes Dalle³ ; Jacqueline Cornish⁴ ; Marco Zecca⁵ ; Sujith Samarasinghe¹ ; Brenda Gibson⁶ ; Franco Locatelli⁷ ; Yves Bertrand⁸ ; Fawzi Abdel-Rahman⁹ ; Gerald Socie¹⁰ ; Mikael Sundin¹¹ ; Arjan Lankester¹² ; Peter Sedlacek¹³ ; Rose Marie Hamladji¹⁴ ; Carsten Heilmann¹⁵ ; Boris Afanasyev¹⁶ ; Rachel Hough¹⁷ ; Cristina Peters¹⁸ ; Peter Bader¹⁹ ; Paul Veys¹
• 刊名：Biology of Blood and Marrow Transplantation
• 出版年：2017
• 出版时间：March 2017
• 年：2017
• 卷：23
• 期：3
• 页码：467-474
• 全文大小：665 K
• 卷排序：23

文摘

Busulfan, cyclophosphamide, and melphalan as a pre–hematopoietic stem cell transplantation conditioning regimen for children with acute myeloid leukemia in first complete remission offers favorable outcomes and is well tolerated. Busulfan, cyclophosphamide, and melphalan offers better chances of reducing relapse rate than total body irradiation/cyclophosphamide or busulfan, cyclophosphamide regimens The use of peripheral blood as stem cell source significantly impairs the outcome, increasing nonrelapse mortality and reducing leukemia-free and overall survival